BII Biocompatibles

TIDMBGC TIDMBII

RNS Number : 2321A

BTG PLC

28 January 2011

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

London, 28 January 2011

BTG PLC ("BTG")

Acquisition of Biocompatibles International Plc ("Biocompatibles")

Offer Update: Admission of New BTG Shares

BTG is pleased to announce, following the Scheme becoming effective in accordance with its terms on 27 January 2011, that applications have been made to the UK Listing Authority and the London Stock Exchange for 68,723,244 New BTG Shares to be admitted to the Official List and to trading on the main market of the London Stock Exchange respectively, in each case to be effective from 8.00 a.m. today ("Admission").

Valid elections for the Partial CVN Alternative were received in respect of 10,722,465 Biocompatibles Shares and accordingly BTG will issue (in aggregate) 10,722,465 Contingent Value Notes. A total of GBP3,034,920 will be paid in cash to Biocompatibles Shareholders who did not elect for the Partial CVN Alternative.

The New BTG Shares are expected to be credited to CREST stock accounts at 8.00 a.m. today. Share certificates for New BTG Shares, certificates in respect of the Contingent Value Notes and cheques in respect of the Partial Cash Consideration are expected to be dispatched to Biocompatibles Shareholders no later than 10 February, 2011.

Following Admission, the issued share capital and voting rights of BTG will be as follows:

The Company's issued share capital will consist of 326,720,846 Ordinary 10p shares with voting rights attached (one vote per ordinary share). There are no shares held in Treasury.

Therefore, the total number of voting rights in the Company upon Admission will be 326,720,846.

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Terms defined in the Scheme Document shall have the same meaning(s) when used in this announcement.

A copy of this announcement will be available on the Company's website at www.btgplc.com by no later than 12:00 noon (London time) on 29 January 2011 (subject to certain restrictions relating to persons resident in restricted jurisdictions).

For further information contact:

BTG

Louise Makin, Chief Executive Officer

+44 (0) 20 7575 0000

Andy Burrows, Director of Investor Relations +44 (0)20 7575 1741 +44 (0)7990 530605 (mobile)

Rolf Soderstrom, Chief Financial Officer +44 (0)20 7575 0000

Financial Dynamics Ben Atwell +44 (0)20 7831 3113

Rothschild (financial adviser and joint sponsor to BTG)

Dominic Hollamby

+44 (0)20 7280 5000

Julian Hudson

+44 (0)20 7280 5000

J.P. Morgan Cazenove (joint sponsor and corporate broker to BTG)

James Mitford

+44 (0)20 7742 4000

Gina Gibson

+44 (0)20 7742 4000

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQPGUGCGUPGGMM

Biocompatibles (LSE:BII)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Biocompatibles (LSE:BII)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024